Navigation Links
Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
Date:10/22/2007

Collaboration with Lentigen Expands Research Applications for RNAi

WALTHAM, Mass., Oct. 22 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has collaborated with Lentigen Corporation to develop a powerful new technology platform that expands applications for RNAi (RNA interference) to critical fields of life sciences research, including neuroscience, immunology and stem cell biology. This advancement, called Thermo Scientific Dharmacon(R) SMARTvector(TM) shRNA Lentiviral Particles, combines Thermo Scientific gene-silencing technologies with Lentigen's expertise in viral-delivery systems. SMARTvector will help researchers overcome common challenges faced when using RNAi, leading to permanent gene silencing in a wide range of cell types.

"With the SMARTvector advancement, we can now effectively deliver stably expressed gene silencing sequences into a broad range of cell types, including those that are difficult to work with, such as primary cells, non-dividing cells, stem cells and neuronal cell lines," said Dr. Ian Jardine, vice president of global research and development for Thermo Fisher Scientific. "Scientists using these cell lines can now harness the power of RNAi in their research, overcoming fundamental limitations in certain existing technologies."

Scientists at Thermo Fisher Scientific have applied innovations in RNAi to develop a novel, dedicated shRNA (short-hairpin RNA) design algorithm that is key to the SMARTvector platform. The algorithm uses criteria unique to shRNA- based silencing for the routine production of highly functional sequences specific to every gene in human, mouse and rat genomes.

"Thermo Fisher Scientific has developed a specialized shRNA design algorithm that greatly enhances the ability to select highly functional gene targeting sequences," added Jardine. "Alternative technologies frequently produce shRNA sequences that are ineffective at silencing the targeted genes, while causing high levels of unintended gene silencing that can lead to flawed experimental results."

By combining shRNA with Lentigen's proprietary viral vector delivery system, the gene silencing sequence is integrated into the host cell genome. This creates permanent gene silencing that cannot be achieved with synthetic siRNAs. Permanent gene silencing is crucial in many types of experiments, including those that examine complex gene networks in drug development and neurobiology.

Dr. Boro Dropulic, founder and chief executive officer of Lentigen, said, "By linking Lentigen's lentiviral technology and production capabilities with the RNAi expertise of Thermo Fisher Scientific, we are giving scientists a new tool that enables a much broader range of experiments involving gene silencing."

Thermo Scientific Dharmacon SMARTvector shRNA Lentiviral Particles can be ordered at http://www.thermo.com/dharmacon .

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com.

Media Contact Information: Investor Contact Information:

Lori Gorski Ken Apicerno

Phone: 781-622-1242 Phone: 781-622-1111

E-mail: lori.gorski@thermofisher.com E-mail: ken.apicerno@thermofisher.com

Website: http://www.thermofisher.com


'/>"/>
SOURCE Thermo Fisher Scientific Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
4. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
7. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
8. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
9. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
10. Inspire Announces Presentations at Two European Scientific Conferences
11. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ Cartilage ... Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - Forecast ... USD 779.8 Million by 2021 from USD 414.6 Million in 2016, ... 2016 to 2021. Continue Reading ... ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 /PRNewswire/ ... Market Research, titled, "Global Cancer Biomarkers Market - Global Opportunity ... biomarkers market is projected to reach $15,737 million by 2022 ... from 2016 to 2022. Omic technologies segment accounted for more ... expected to maintain its dominance during the forecast period. ...
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
Breaking Medicine Technology:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... advisory organization, is proud to announce it has added CXC Solutions (CXC) as ... management solutions. These solutions are tailored to help benefits advisors reduce operating ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER ... all the knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, ... To access more than 9,000 documents, webinars and videos available online, visit the ...
(Date:12/6/2016)... ... December 06, 2016 , ... “Tatiana Sibirskaya: A Life Devoted ... of sacrifice and enlightenment. , “Tatiana Sibirskaya: A Life Devoted to ... for creative outlets, Carolyn gravitated toward writing through the inspiration of her aging ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) ... 125 for their industry leading training methods that engage their associates and link ... the global elite in employer-sponsored training and development programs. , “The 2017 Training ...
(Date:12/5/2016)... ... 2016 , ... For many years, Andrew G. Zubinas has accumulated ... beauty of the Lithuanian language and its poetry inspired him in writing ... lyrically explores all aspects of a living, breathing forest where nothing ever stays the ...
Breaking Medicine News(10 mins):